Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency

Poly ADP ribose polymerase (PARP) inhibitors are mainly used in treating BRCA-mutant cancers, and their application in novel therapies to expand their benefit is of interest in personalized medicine. A recent report showed that pharmacological targeting of PARP increases the sensitivity of cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Wenyan, Li, Guangyao, Lei, Changhai, Qian, Kewen, Zhang, Shuyi, Zhao, Jian, Hu, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334837/
https://www.ncbi.nlm.nih.gov/pubmed/37441599
http://dx.doi.org/10.7150/thno.82144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334837/
https://www.ncbi.nlm.nih.gov/pubmed/37441599
http://dx.doi.org/10.7150/thno.82144

Ejemplares similares